RE:RE:RE:RE:RE:RE:RE:GRC conversion1condor wrote: Sadly for the ole GRC investors...this stock would need to get to 2+ bucks for them to break even.
Yep. Sad indeed. A whole lot of wealth destruction. And the Logiq / Aston Hill story is much worse.
I think there's value here but as I've said before, lots of risk and very rich insider compensation for very poor past performance. Will be "interesting" to learn in the next Q report just how much they paid Parry as he transitioned to senior advisor. I mean they paid Annie $350k or thereabouts when they let her go, or some stupid number around there. I fear Parry's gift will be truly astounding.
We're coming to the end of Q2. Aside from the restructuring fee attributable to Parry's transition, I expect to see Q-over-Q royalty revenues improve to somewhere around $1.2m. If BWLK remains above $5 (even on little-to-no volume) they'll see a big unrealized gain on the 400,000 warrants. Lattice Biologics shares have also shot up from .05 at Mar 31 to .10 today. The move has been on near 0 volume, but if prices hold to end of Q then they'll see a big paper gain of around 900k.
So Q2 numbers could look pretty nice with these illusory/volatile gains. Will likely be enough to mask the effects of the Parry payout. And we'll also see how accretive the Logiq biz truly is (if at all).